FOQUEST IN THE TREATMENT OF ADULT ADHD

12/11/2021
Juanita Beaudry

Purpose of Research
Individuals who suffer from adult ADHD often suffer from other emotional or psychiatric disorders as well, including anxiety disorders and depression. Previous studies of treatments for adult ADHD have focused on individuals who suffer from ADHD only. The purpose of this study is to examine the effect of medication treatment for ADHD on both adult ADHD as well as how it affects anxiety and mood disorders. Since it is quite common for individuals to have other disorders, it is important that clinicians understand what treatment options will be best for these people.

Who Can Participate? 
Adults aged 18 to 65 years, who think they may have ADHD (the previous diagnosis not necessary; we will determine diagnosis) as well as anxiety or depression.

What is involved? 
This study involves undergoing an interview assessment to see if your symptoms may fit the study criteria. If you do, and you provide your consent to participate, this study involves taking medication for adult ADHD on a daily basis. The study will last for a total period of 15 weeks and you will be asked to attend 10 visits. You will be given the study medication, Foquest (methylphenidate hydrochloride controlled-release capsules), for part of the study a placebo pill (that has no medication) for part of the study. Neither you nor the study team will know if you are taking the medication or the placebo. You will meet with a study doctor and study team members at each visit. Visits involve completing questionnaires about your symptoms, having your blood pressure and pulse checked, and discussing how you have been feeling.

Location of Study: Centre for Anxiety, Attention Deficit and Trauma 1057 Main St W, Hamilton, ON

How Can I Join This Study? 
For information contact us at 905 921 7644; email: macanxietyresearch@gmail.com

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram